• Anagliptin (SK-0403): Applied DPP-4 Inhibition in Vascular R

  2026-05-14

  Unlock the dual power of Anagliptin (SK-0403) for both metabolic and vascular research: its ability to induce vasorelaxation via Kv channel and SERCA pump activation offers unique insight beyond glycemic control. This guide delivers protocol detail, troubleshooting, and advanced workflow strategies grounded in recent experimental breakthroughs.

• Triptolide (PG490): Precision Tool for Cancer and Immunology

  2026-05-13

  Triptolide (PG490) delivers nanomolar-potency inhibition of key inflammatory and cancer signaling pathways, enabling robust, reproducible research in oncology and immunology. This guide synthesizes experimental workflows and troubleshooting strategies—leveraging APExBIO’s validated Triptolide—for researchers seeking superior data clarity in cell-based and in vivo disease models.

• Cyclic di-GMP: Protocols for Biofilm & Immune Modulation Res

  2026-05-13

  Cyclic di-GMP stands at the crossroads of bacterial persistence and immune signaling, unlocking new workflows in both biofilm biology and cancer immunotherapy studies. This article delivers stepwise protocols, troubleshooting insights, and actionable context from the latest research, equipping scientists to harness this potent intracellular second messenger for advanced applications.

• TaqI Restriction Endonuclease: Fast, Reliable DNA Digestion

  2026-05-12

  TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific DNA cleavage for applications requiring quick turnaround, such as cloning, analysis of plasmid or PCR products, and genomic DNA manipulation. It is not intended for diagnostic or medical use and should only be applied in research workflows where fast, efficient sticky end generation at the 5'…TCGA…3' site is required.

• Canagliflozin (hemihydrate): Precision for Glucose Metabolis

  2026-05-12

  This scenario-driven article equips biomedical researchers and lab technicians with practical, evidence-based strategies for using Canagliflozin (hemihydrate) (SKU C6434) in cell viability, proliferation, and cytotoxicity assays targeting glucose metabolism pathways. We address real laboratory challenges—ranging from assay specificity to product reliability—drawing on recent literature and validated best practices to ensure reproducibility and translational value.

• GSK2606414: Precision PERK Inhibition for ER Stress Research

  2026-05-11

  Explore how GSK2606414, a potent PERK inhibitor, enables advanced ER stress research and unfolded protein response modulation. Discover its distinct mechanism, assay guidance, and critical insights linking redox biology and translational models.

• A Tunable Human Intestinal Organoid System: Balancing Self-R

  2026-05-11

  This study introduces a scalable human intestinal organoid platform that achieves a controlled equilibrium between stem cell self-renewal and differentiation using small molecule pathway modulators. The findings address a longstanding barrier in organoid culture, enabling greater cellular diversity and proliferative capacity under a single culture condition, thus expanding high-throughput research applications.

• Topological Stress Drives Persistent rDNA Damage and PML-Nuc

  2026-05-10

  This study demonstrates that topological stress and RNA polymerase I inhibition induce persistent DNA lesions in ribosomal DNA, resulting in the formation of PML-nucleolar associations (PNAs). These findings clarify how specific genotoxic stresses trigger nucleolar compartmental changes linked to genome stability, with direct implications for understanding DNA repair, senescence, and cancer biology.

• Dehydroabietic Acid in Precision Adipocyte Modulation Resear

  2026-05-09

  Explore how Dehydroabietic acid functions as a dual PPAR-α/γ agonist for advanced metabolic disorder research. This article uniquely analyzes its role in targeted adipocyte modulation and practical assay optimization.

• Canagliflozin Remodels Mitochondria in Diabetic Kidney Disea

  2026-05-08

  This study demonstrates that canagliflozin, a potent SGLT2 inhibitor, promotes both structural and bioenergetic improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. The findings suggest that canagliflozin’s renoprotective effects extend beyond glycemic control, providing a mechanistic foundation for its use in diabetes and kidney disease research.

• URB597 (KDS-4103): Dissecting FAAH Inhibition Beyond Neuropl

  2026-05-08

  Explore how URB597, a potent FAAH inhibitor, enables rigorous mechanistic dissection of endocannabinoid signaling, with a focus on experimental precision and translational relevance. This unique review moves beyond neuroplasticity to illuminate novel assay design strategies for in vivo FAAH inhibition and neuroinflammation studies.

• Mapping GCGR Small-Molecule Binding: Insights from MK 0893 C

  2026-05-07

  This study leverages crystallographic and dynamic structural data to delineate binding sites of small-molecule glucagon receptor antagonists, notably MK 0893. By systematically docking and simulating multiple clinical candidates, the work advances our understanding of GCGR modulation and provides a foundation for rational drug design targeting type 2 diabetes.

• Araucarene Diterpenes Promote β Cell Regeneration and Glucos

  2026-05-07

  This study from Xiamen University and collaborators identifies 16 araucarene diterpenes from Agathis dammara, including 11 new compounds, and demonstrates their hypoglycemic effects in a zebrafish model. The research reveals that these diterpenes promote pancreatic β cell regeneration and enhance glucose uptake, offering mechanistic insights relevant to diabetes research.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-05-06

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents proteolytic degradation during protein extraction without interfering with divalent cation-dependent workflows. It is appropriate for Western blotting, co-immunoprecipitation, and kinase assays, but should not be used where EDTA-sensitive metalloprotease inhibition is required.

• Stiripentol: LDH Inhibitor for Epilepsy & Metabolic Assays

  2026-05-06

  Stiripentol offers precise, noncompetitive LDH inhibition for advanced epilepsy and immunometabolic research. Its solubility profile and validated workflow parameters make it a trusted choice for dissecting lactate metabolism in cellular and animal models.

16458 records 1/1098 page Next 12345 下5页 Last page